AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7746341 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural transplantation
Number of subjects: 0
Study 1827344 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% w/w CD 271 alcoholic gel
Number of subjects: 72
Study 1827344 — intervention group
Group type: COMPARATOR
Intervention: 0.025% w/w tretinoin gel
Number of subjects: 72
Study 1827344 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% w/w CD 271 alcoholic gel
Number of subjects: 72
Study 7313587 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 2.0 g on 2 consecutive days
Number of subjects: 50
Study 7313587 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole 2.0 g as a single dose
Number of subjects: 50
Study 7313587 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 200 mg 3 times daily for 1 week
Number of subjects: 50
Study 30870364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone (62.5 mg/mL)
Number of subjects: 46
Study 30870364 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic gentamicin (40 mg/mL)
Number of subjects: 46
Study 28403362 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% (w/v) hyaluronic acid (HA)
Number of subjects: 40
Study 28403362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 26215224 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercises
Number of subjects: 44
Study 26215224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory exercises
Number of subjects: 44
Study 26215224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task exercises
Number of subjects: 44
Study 22892021 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration perception threshold (VPT) measured using a neurothesiometer
Number of subjects: 400
Study 22892021 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-g Semmes-Weinstein monofilament (SWF) test
Number of subjects: 400
Study 22892021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests (VPT and SWF)
Number of subjects: 400
Study 22892021 — intervention group
Group type: EXPERIMENTAL
Intervention: VPT
Number of subjects: 400
Study 22892021 — intervention group
Group type: EXPERIMENTAL
Intervention: SWF
Number of subjects: 400
Study 22892021 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between VPT and SWF
Number of subjects: 400
Study 23330199 — intervention group
Group type: EXPERIMENTAL
Intervention: Encephabol (suspension form, daily dosage 200‐250 mg, or 12‐15 mg/kg) for 2 months
Number of subjects: 40
Study 23330199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 40
Study 23330199 — intervention group
Group type: EXPERIMENTAL
Intervention: Encephabol
Number of subjects: 40
Study 19196080 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise training (HI)
Number of subjects: 18
Study 19196080 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise training (MI)
Number of subjects: 18
Study 19196080 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 18
Study 17300287 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 100 mg t.i.d.
Number of subjects: 46
Study 17300287 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 200 mg t.i.d.
Number of subjects: 46
Study 17300287 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 46
Study 15362772 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus thymosin alpha1 postoperatively (Group A)
Number of subjects: 57
Study 15362772 — intervention group
Group type: COMPARATOR
Intervention: TACE postoperatively (Group B)
Number of subjects: 57
Study 15362772 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy only (Group C)
Number of subjects: 57
Study 11589257 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib sodium (10 mg BID)
Number of subjects: 17
Study 11589257 — intervention group
Group type: COMPARATOR
Intervention: ketorolac (15 mg QID)
Number of subjects: 17
Study 11589257 — intervention group
Group type: COMPARATOR
Intervention: naproxen (500 mg BID)
Number of subjects: 17
Study 11589257 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 9433424 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance dose 3.0 mg/kg daily)
Number of subjects: 94
Study 9433424 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (2.5 mg/kg daily then 5.0 mg/kg daily)
Number of subjects: 94
Study 7986761 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact (intervention arm)
Number of subjects: 100
Study 7986761 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 100
Study 7986761 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis by intention to treat (intervention)
Number of subjects: 100
Study 2185154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 40
Study 2185154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 40
Study 453504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 66% for the first 3 minutes
Number of subjects: 2
Study 453504 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic based on oxygen 66%, nitrous oxide 33% and halothane 0.4%
Number of subjects: 2
Study 30593457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG therapy
Number of subjects: 50
Study 30593457 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG ± intradermal HS-410 therapy
Number of subjects: 50
Study 28634659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moor bath (42 °C, 20 min) followed by a resting period (20 min)
Number of subjects: 78
Study 25468282 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (15 min, three times a week for four weeks)
Number of subjects: 108
Study 25468282 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care with routine hemodialysis treatment)
Number of subjects: 108
Study 22833377 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod (25 mg/day for the first 4 weeks, then 50 mg/day for the subsequent 20 weeks) with MTX (6 or 8 mg/week)
Number of subjects: 253
Study 22833377 — intervention group
Group type: COMPARATOR
Intervention: Placebo with MTX (6 or 8 mg/week)
Number of subjects: 253
Study 22833377 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod with MTX
Number of subjects: 253
Study 21031342 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease-inhibitor-modulating-matrix (ORC/collagen matrix) changed daily
Number of subjects: 19
Study 21031342 — intervention group
Group type: COMPARATOR
Intervention: Good standard wound care
Number of subjects: 19
Study 19387178 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural etanercept 2 mg
Number of subjects: 24
Study 19387178 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural etanercept 4 mg
Number of subjects: 24
Study 19387178 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural etanercept 6 mg
Number of subjects: 24
Study 19387178 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (Control)
Number of subjects: 24
Study 17979587 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily multilayer-release methylphenidate (MLR) at a stable dose of 32.0 mg
Number of subjects: 90
Study 17979587 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily immediate-release methylphenidate (IR-MPH) at a stable dose of 32.5 mg
Number of subjects: 90
Study 15530203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying alone among girls
Number of subjects: 117
Study 15530203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying alone among boys
Number of subjects: 117
Study 15530203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying in groups among girls
Number of subjects: 117
Study 15530203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying in groups among boys
Number of subjects: 117
Study 11495122 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with low working-memory capacities who detected their name in an irrelevant message
Number of subjects: 0
Study 11495122 — intervention group
Group type: COMPARATOR
Intervention: Subjects with higher working-memory capacities (implied control group)
Number of subjects: 0
Study 9671000 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab with low-dose weight-adjusted heparin
Number of subjects: 144
Study 9671000 — intervention group
Group type: COMPARATOR
Intervention: placebo with standard-dose, weight-adjusted heparin
Number of subjects: 144
Study 9671000 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (combined analysis from EPIC and EPILOG trials)
Number of subjects: 144
Study 9671000 — intervention group
Group type: COMPARATOR
Intervention: DCA patients compared to PTCA patients
Number of subjects: 144
Study 7821192 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cannulation
Number of subjects: 0
Study 7821192 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cannulation
Number of subjects: 0
Study 2688764 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbimide (CC)
Number of subjects: 0
Study 2688764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 0
Study 1103576 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (rapidly falling dosage)
Number of subjects: 0
Study 1103576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1103576 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 31270800 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aerosolised prostacyclin (20 ng/kg/min)
Number of subjects: 22
Study 31270800 — intervention group
Group type: COMPARATOR
Intervention: Inhaled saline (NaCl, 9 mg/mL)
Number of subjects: 22
Study 28911799 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol proprionate (CP)
Number of subjects: 16
Study 28911799 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betamethasone diproprionate (BDP)
Number of subjects: 16
Study 28911799 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 16
Study 26609891 — intervention group
Group type: EXPERIMENTAL
Intervention: Perospirone or aripiprazole
Number of subjects: 100
Study 23955418 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (150 mg/day)
Number of subjects: 54
Study 23955418 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (200 mg/day)
Number of subjects: 54
Study 23955418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20862509 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 25
Study 20862509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19245725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 68
Study 19245725 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 68
Study 17131249 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eye drops twice daily
Number of subjects: 10
Study 17131249 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate eye drops twice daily
Number of subjects: 10
Study 15590250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (0.05 mg) with mepivacaine (100 mg)
Number of subjects: 40
Study 15590250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (0.1 mg) with mepivacaine (100 mg)
Number of subjects: 40
Study 15590250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (0.15 mg) with mepivacaine (100 mg)
Number of subjects: 40
Study 15590250 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 mg neostigmine) with mepivacaine (100 mg)
Number of subjects: 40
Study 11392367 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education
Number of subjects: 0
Study 11392367 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 0
Study 11392367 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based video education
Number of subjects: 0
Study 11392367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formal asthma education)
Number of subjects: 0
Study 9463302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin/chamomile extract preparation (Diarrhoesan)
Number of subjects: 79
Study 9463302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 8076074 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial appendicectomy
Number of subjects: 20
Study 8076074 — intervention group
Group type: COMPARATOR
Intervention: Saving the right atrial appendix
Number of subjects: 20
Study 3525428 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 200-400 mg
Number of subjects: 10
Study 3525428 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 100 mg
Number of subjects: 10
Study 3525428 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 50-200 mg
Number of subjects: 10
Study 3525428 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (various doses)
Number of subjects: 10
Study 3525428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28636433 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS‐004 dendritic cell therapy administered monthly after ART initiation during acute HIV infection
Number of subjects: 6
Study 28636433 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS‐004 dendritic cell therapy
Number of subjects: 6
Study 27633780 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report method
Number of subjects: 135
Study 27633780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart-stimulated recall method
Number of subjects: 135
Study 27633780 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral rehearsal method
Number of subjects: 135
Study 27633780 — intervention group
Group type: COMPARATOR
Intervention: Direct observation (gold-standard)
Number of subjects: 135
Study 25185281 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (standardized allergen vaccine) for 3 years
Number of subjects: 102
Study 25185281 — intervention group
Group type: COMPARATOR
Intervention: ST (symptomatic therapy)
Number of subjects: 102
Study 23782816 — intervention group
Group type: EXPERIMENTAL
Intervention: Community resource centers (intervention)
Number of subjects: 24000
Study 20728275 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 20728275 — intervention group
Group type: COMPARATOR
Intervention: Low dose of naloxone (0.02 mg/kg)
Number of subjects: 0
Study 20728275 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of naloxone (0.14 mg/kg)
Number of subjects: 0
Study 18266852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin 10/40 mg
Number of subjects: 424
Study 18266852 — intervention group
Group type: COMPARATOR
Intervention: Doubling the statin dose
Number of subjects: 424
Study 16009156 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of levonorgestrel (1.5 mg)
Number of subjects: 30
Study 16009156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of levonorgestrel (1.5 mg)
Number of subjects: 30
Study 16009156 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 5)
Number of subjects: 30
Study 12834639 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm contrast medium
Number of subjects: 100
Study 12834639 — intervention group
Group type: COMPARATOR
Intervention: Cold contrast medium
Number of subjects: 100
Study 10638905 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia (PCIA) with ropivacaine 0.2%
Number of subjects: 35
Study 10638905 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIVA) with nicomorphine
Number of subjects: 35
Study 8964871 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 12
Study 8964871 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (RI)
Number of subjects: 12
Study 1515660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg b.i.d.
Number of subjects: 117
Study 1515660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 6366809 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg naproxen daily for 7 days
Number of subjects: 79
Study 6366809 — intervention group
Group type: COMPARATOR
Intervention: 2 g acetylsalicylic acid daily for 7 days
Number of subjects: 79
Study 30216238 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 333
Study 30216238 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter sedentary bouts (1-4 min)
Number of subjects: 333
Study 30216238 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer sedentary bouts (5-9 min, 10-14 min, ≥15 min)
Number of subjects: 333
Study 30216238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 333
Study 30216238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (ST) and breaks in sedentary time (BST/ST)
Number of subjects: 333
Study 28840431 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Number of subjects: 27
Study 28840431 — intervention group
Group type: COMPARATOR
Intervention: Control (no photobiomodulation therapy)
Number of subjects: 27
Study 26969188 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education for GPs
Number of subjects: 785
Study 24405028 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 38
Study 24405028 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 38
Study 24405028 — intervention group
Group type: COMPARATOR
Intervention: Non-stretching (control condition)
Number of subjects: 38
Study 21676554 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) plus vaginal brachytherapy (VBT)
Number of subjects: 527
Study 21676554 — intervention group
Group type: COMPARATOR
Intervention: Vaginal irradiation alone (VBT)
Number of subjects: 527
Study 20197772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus DNA detection in Guthrie cards
Number of subjects: 243
Study 20197772 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no adenovirus DNA detected)
Number of subjects: 243
Study 17503668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART) with zidovudine/lamivudine
Number of subjects: 139
Study 16803794 — intervention group
Group type: EXPERIMENTAL
Intervention: Widex Diva SP3 device with stimulus generated by Widex Diva SD-9 hearing aid
Number of subjects: 43
Study 12642825 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 322
Study 12642825 — intervention group
Group type: COMPARATOR
Intervention: Control (unexposed)
Number of subjects: 322
Study 11116663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 37000
Study 8814744 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ganciclovir 0.15% gel
Number of subjects: 0
Study 8814744 — intervention group
Group type: COMPARATOR
Intervention: Topical acyclovir 3% ointment
Number of subjects: 0
Study 1711089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (radiation and hyperthermia with bleomycin)
Number of subjects: 56
Study 1711089 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (50-70 Gy)
Number of subjects: 56
Study 6601941 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy continued intraoperatively and postoperatively
Number of subjects: 100
Study 6601941 — intervention group
Group type: COMPARATOR
Intervention: Propranolol therapy discontinued
Number of subjects: 100
Study 31583748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training (CBCT) administered for 20 hours across 8 to 10 weeks to parents (n = 25)
Number of subjects: 39
Study 31583748 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 14)
Number of subjects: 39
Study 31090751 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive flap
Number of subjects: 17
Study 31090751 — intervention group
Group type: COMPARATOR
Intervention: Trapezoidal flap
Number of subjects: 17
Study 28576403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PHACO)
Number of subjects: 57
Study 28576403 — intervention group
Group type: COMPARATOR
Intervention: Small incision cataract surgery (SICS)
Number of subjects: 57
Study 28576403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PHACO and SICS
Number of subjects: 57
Study 26135275 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention; details on dosage and duration not available.
Number of subjects: 0
Study 26135275 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on intervention not available.
Number of subjects: 0
Study 23638803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (Ozurdex)
Number of subjects: 102
Study 23638803 — intervention group
Group type: COMPARATOR
Intervention: Sectorial laser photocoagulation
Number of subjects: 102
Study 23638803 — intervention group
Group type: COMPARATOR
Intervention: Panretinal laser photocoagulation
Number of subjects: 102
Study 21185347 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS®-methylphenidate hydrochloride (MPH) 18, 36 or 72 mg
Number of subjects: 0
Study 21185347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19723572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxinus excelsior L. seed extract (1.0 g)
Number of subjects: 16
Study 19723572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wheat bran)
Number of subjects: 16
Study 17257972 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 212
Study 17257972 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 212
Study 17257972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 212
Study 15189519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing from nontraditional or alternate sites
Number of subjects: 0